Xeris Biopharma (NASDAQ:XERS) Director James Aloysius Brady Sells 10,834 Shares of Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Director James Aloysius Brady sold 10,834 shares of the stock in a transaction dated Monday, March 30th. The shares were sold at an average price of $5.54, for a total value of $60,020.36. Following the transaction, the director directly owned 89,166 shares in the company, valued at approximately $493,979.64. This represents a 10.83% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Xeris Biopharma Price Performance

XERS opened at $6.04 on Friday. The firm has a market cap of $1.04 billion, a P/E ratio of -603.40 and a beta of 0.77. The company has a debt-to-equity ratio of 16.10, a quick ratio of 1.57 and a current ratio of 2.19. The business has a 50 day moving average price of $6.36 and a 200 day moving average price of $7.30. Xeris Biopharma Holdings, Inc. has a twelve month low of $3.81 and a twelve month high of $10.08.

Xeris Biopharma (NASDAQ:XERS) last announced its quarterly earnings results on Monday, March 2nd. The company reported $0.06 EPS for the quarter, beating the consensus estimate of $0.03 by $0.03. Xeris Biopharma had a negative return on equity of 5.33% and a net margin of 0.19%.The company had revenue of $85.81 million for the quarter, compared to the consensus estimate of $86.00 million. Research analysts forecast that Xeris Biopharma Holdings, Inc. will post -0.41 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. Wall Street Zen raised shares of Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a research report on Saturday, March 7th. Weiss Ratings raised Xeris Biopharma from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Wednesday, March 4th. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Xeris Biopharma in a research note on Monday, March 2nd. Finally, Barclays assumed coverage on Xeris Biopharma in a research report on Monday, December 8th. They set an “overweight” rating and a $9.00 price objective for the company. Four equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, Xeris Biopharma presently has an average rating of “Moderate Buy” and a consensus target price of $10.80.

Institutional Trading of Xeris Biopharma

A number of hedge funds have recently bought and sold shares of XERS. Royal Bank of Canada increased its holdings in shares of Xeris Biopharma by 1,411.2% during the 1st quarter. Royal Bank of Canada now owns 213,084 shares of the company’s stock worth $1,170,000 after purchasing an additional 198,984 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Xeris Biopharma by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 83,982 shares of the company’s stock valued at $461,000 after buying an additional 3,594 shares during the period. Millennium Management LLC grew its position in Xeris Biopharma by 19.0% during the first quarter. Millennium Management LLC now owns 2,317,972 shares of the company’s stock worth $12,726,000 after buying an additional 369,420 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in Xeris Biopharma by 75.4% during the first quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock valued at $15,317,000 after acquiring an additional 1,199,435 shares during the period. Finally, Caxton Associates LLP bought a new position in Xeris Biopharma during the first quarter valued at about $170,000. 42.75% of the stock is owned by institutional investors.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.